GeoVax Labs, Inc. (GOVX) intrinsic value & 10-year financials
GeoVax Labs, Inc. (GOVX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 13.0% a year to $2.5M, with an average return on invested capital of 860.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.24
- Revenue (FY2025)
- $2.5M
- Revenue growth (10-yr CAGR)
- 13.0%
- ROIC (10-yr avg)
- 860.7%
- Free cash flow (FY2025)
- -$21.5M
GOVX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $2.5M | -$21.5M | — | -$21.5M | -869.3% | -4985.9% |
| FY2024 | $4.0M | -$25.0M | — | -$24.7M | -635.8% | 4355.4% |
| FY2023 | $0 | -$26.0M | — | -$25.2M | — | 3767.4% |
| FY2022 | $81.5K | -$14.0M | — | -$19.2M | -17207.5% | 198.5% |
| FY2021 | $385.5K | -$18.6M | — | -$11.2M | -4862.7% | 522.2% |
| FY2020 | $1.8M | -$3.0M | — | -$2.9M | -154.5% | 291.1% |
| FY2019 | $1.2M | -$2.4M | — | -$1.4M | -201.8% | 169.5% |
| FY2018 | $963.2K | -$2.6M | — | — | -266.1% | 261.0% |
| FY2017 | $1.1M | -$2.2M | — | -$1.7M | -202.2% | 5389.8% |
| FY2016 | $828.9K | -$3.3M | — | — | -394.9% | -1361.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
GeoVax Labs, Inc. is a consistent compounder, expanding top-line revenue at 13.0% annually over the past decade.
GeoVax Labs, Inc. has historically struggled to out-earn its cost of capital, averaging just 5.7% ROIC.
GeoVax Labs, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, GeoVax Labs, Inc. is modeled at 13.0% normalized earnings growth with a 5.1% bond-yield adjustment.